Information  X 
Enter a valid email address

Proteome Sciences (PRM)


Friday 26 June, 2020

Proteome Sciences

Result of AGM

RNS Number : 2477R
Proteome Sciences PLC
26 June 2020

26 June 2020







Proteome Sciences plc

("Proteome Sciences" or the "Company")


Result of Annual General Meeting (AGM)


The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.


The Company has prepared a new presentation for shareholders and a copy will be available on the Company's website later today.



For further information:


Proteome Sciences plc

Dr Ian Pike, Interim Chief Executive Officer & Chief Scientific Officer


Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116


Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656



About Proteome Sciences plc. ( )


Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.


The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t